1 / 11

New Diabetes Drugs DPP-4 Inhibitors Exenatide

New Diabetes Drugs DPP-4 Inhibitors Exenatide. Incretin effect. GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose Type 2 diabetics little incretin effect Reduced GLP-1 secretion GIP lost insulinotropic property GLP-1 broken down by DPP-4

winslow
Download Presentation

New Diabetes Drugs DPP-4 Inhibitors Exenatide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Diabetes DrugsDPP-4 InhibitorsExenatide

  2. Incretin effect • GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose • Type 2 diabetics little incretin effect • Reduced GLP-1 secretion • GIP lost insulinotropic property • GLP-1 broken down by DPP-4 • Only for type 2 diabetes

  3. DPP-4 Inhibitors: Sitagliptin, Vildagliptin • Inhibits incretin breakdown • Indirectly increase own insulin secretion • Moderate HBA1c reduction (~1%) • Which one to choose?

  4. DPP-4 Inhibitors: Sitagliptin, Vildagliptin • Start • 2nd line: Metformin or Sulphonylurea + HBA1c ≥ 6.5% + not suitable for other one • 3rd line: Metformin + Sulphonylurea + HBA1c ≥ 7.5% • Thiazolidinedione is an alternative in 2nd line case but not 3rd • Continue • HBA1c reduces by ≥ 0.5% in 6 months

  5. DPP-4 Inhibitor vsThiazolidinedione • DPP-4 Inhibitor if: • Weight gain would cause significant problem • Thiazolidinedione contraindicated • eg heart failure • Previous intolerance or poor response to Thiazolidinedione

  6. Incretin effect • GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose • Type 2 diabetics little incretin effect • Reduced GLP-1 secretion • GIP lost insulinotropic property • GLP-1 broken down by DPP-4 • Only for type 2 diabetes

  7. GLP 1 Mimetic - Exenatide Effects: • Stimulates post-prandial insulin secretion • Slows gastric emptying • Reduces appetite Administered: • Subcutaneous injection • Twice daily

  8. Exenatide • Less hypos compared to insulin • BIG benefit of weight loss • Only licensed to lower blood sugars, not as weight loss agent • Nausea and vomiting • £830 per person per year

  9. Exenatide • Start: • BMI ≥ 35 (+ probs assoc. with high wt) • BMI < 35 + insulin unacceptable or weight loss beneficial to co-morbidities • Continue Metformin and Sulphonylurea • Combination with insulin • Continue: • HbA1c reduction ≥ 1.0% AND • Initial body weight reduction ≥ 3%

  10. Conclusion • Metformin still first line • DPP-4 Inhibitors alternative where Thiazolidinediones were previously only other oral option • Exenatide - good for weight loss but ?help in sugar control • Further new drugs on their way

More Related